AI Terminal
Embla Medical hf
Transaction in Own Shares • Jan 12, 2026
8210_rns_2026-01-12_41fc0f4d-7d72-4a7a-9143-d2b9fd2279cf.htm
Transaction in Own Shares
Open in ViewerOpens in native device viewer
Embla Medical hf: Transactions in relation to Share Buyback Program
Announcement no. 1/2026
12 January 2026
Reykjavik, Iceland/Copenhagen, Denmark, 12 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025.
During the period 5 January to 9 January 2026 Embla Medical has acquired 41,000 shares under the Program at the average price of DKK 32.37. Following the transactions below, the Company holds 2,709,596 shares, corresponding to 0.63% of the Company’s total share capital.
| Transaction date | No. of shares | Avg. purchase price in DKK | Transaction value in DKK | |
| 5 January 2026 | 6,853 | 32.08 | 219,810 | |
| 6 January 2026 | 7,147 | 32.13 | 229,669 | |
| 7 January 2026 | 7,000 | 32.45 | 227,122 | |
| 8 January 2026 | 7,000 | 32.40 | 226,800 | |
| 9 January 2026 | 13,000 | 32.60 | 423,800 | |
| Total | 41,000 | 32.37 | 1,327,201 |
The purpose of the Program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy. The Program will end no later than 31 December 2026, but the Company is entitled to discontinue the Program at any time.
The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.46% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million.
The Program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission’s delegated regulation 2016/1052.
Further information
Klaus Sindahl, Head of Investor Relations, [email protected], +45 5363 0134
Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors
About Embla Medical
Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. Embla Medical is home to several leading brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women’s Empowerment Principles and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees. www.emblamedical.com
This information was brought to you by Cision http://news.cision.com
[
20260112 Embla Announcement 1 Share Repurchase Specification](https://mb.cision.com/Main/18404/4291031/3870425.pdf)